Johnson M, Rennard S. Alternative mechanisms for long-acting beta(2)-adrenergic agonists in COPD. Chest. 2001;120(1):258–270. https://doi.org/10.1378/chest.120.1.258..
DOI: 10.1378/chest.120.1.258
Paggiaro PL, Giannini D, Di Franco A, Testi R. Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group. Eur Respir J. 1996;9(8):1689–1695. https://doi.org/10.1183/09031936.96.09081689..
DOI: 10.1183/09031936.96.09081689
Perera BJ. Salmeterol multicentre asthma research trial (SMART): interim analysis shows increased risk of asthma related deaths. Ceylon Med J. 2003;48(3):99. https://doi.org/10.4038/cmj.v48i3.3362..
DOI: 10.4038/cmj.v48i3.3362
Williams C. Cause of death in the SMART Trial. Chest. 2006;130(3):929–930. https://doi.org/10.1378/chest.130.3.929-a..
DOI: 10.1378/chest.130.3.929-a
Визель АА, Визель ИЮ. Хроническая обструктивная болезнь легких – от истоков к современности (исторический обзор литературы). Туберкулез и болезни легких. 2019;97(2):42–49. https://doi.org/10.21292/2075-1230-2019-97-2-42-49..
DOI: 10.21292/2075-1230-2019-97-2-42-49
Чучалин АГ, Авдеев СН, Айсанов ЗР, Белевский АС, Васильева ОС, Геппе НА и др. Бронхиальная астма: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):393–447. https://doi.org/10.18093/0869-0189-2022-32-3-393-447..
DOI: 10.18093/0869-0189-2022-32-3-393-447
Reddel HK, Bateman ED, Schatz M, Krishnan JA, Cloutier MM. A Practical guide to implementing SMART in asthma management. J Allergy Clin Immunol Pract. 2022;10(1 Suppl.):31–38. https://doi.org/10.1016/j.jaip.2021.10.011..
DOI: 10.1016/j.jaip.2021.10.011
Ненашева НМ. Концепция «противовоспалительный бронхолитик»: гармония между потребностями пациента и целями врача при бронхиальной астме любой степени тяжести. Практическая аллергология. 2021;(1):8–16. https://doi.org/10.46393/2712-9667_2021_1_8-16..
DOI: 10.46393/2712-9667_2021_1_8-16
Демко ИВ, Мамаева МГ, Собко ЕА, Крапошина АЮ, Гордеева НВ. Клинический опыт применения будесонида/формотерола у пациентов с хронической обструктивной болезнью легких. Медицинский совет. 2021;(16):26–31. https://doi.org/10.21518/2079-701X-2021-16-26-31..
DOI: 10.21518/2079-701X-2021-16-26-31
Aryani T, Rahmawati RK, Cintyadewi NP, Puspitasari AD, Rasyid AN, Samirah. Patterns of bronchodilator therapy in asthmatic outpatients. J Public Health Afr. 2023;14(Suppl. 1):2533. https://doi.org/10.4081/jphia.2023.2533..
DOI: 10.4081/jphia.2023.2533
Vinnikov D, Raushanova A, Mukatova I, Nurpeissov T, Кushekbayeva A, Toxarina A et al. Asthma control in Kazakhstan: need for urgent action. BMC Pulm Med. 2023;23(1):7. https://doi.org/10.1186/s12890-022-02287-2..
DOI: 10.1186/s12890-022-02287-2
Nishi MK, Akter S, Tania IJ, Shams N, Khatun S. Use of Drugs considering route of administration on drug prescription pattern for bronchial asthma in a tertiary level hospital. Mymensingh Med J. 2023;32(1):73–75. Available at: https://pubmed.ncbi.nlm.nih.gov/36594304.https://pubmed.ncbi.nlm.nih.gov/36594304
Nishi MK, Akter S, Tania IJ, Shams N, Khatun S. Use of Drugs considering route of administration on drug prescription pattern for bronchial asthma in a tertiary level hospital. Mymensingh Med J. 2023;32(1):73–75. Available at: https://pubmed.ncbi.nlm.nih.gov/36594304.https://pubmed.ncbi.nlm.nih.gov/36594304
Salciccioli JD, Israel E. As-needed inhaled corticosteroids as add-on therapy versus SMART therapy: an evolving understanding of the two approaches in the management of moderate-to-severe asthma. Curr Opin Pulm Med. 2023;29(3):209–214. https://doi.org/10.1097/MCP.0000000000000961..
DOI: 10.1097/MCP.0000000000000961
Larenas-Linnemann D, Romeo J, Ariue B, Oppenheimer J. American College of Allergy, Asthma and Immunology members’ preferred steps 1 to 3 asthma maintenance and reliever therapy and incomplete insurance coverage indicated as main practice hurdle. Ann Allergy Asthma Immunol. 2023;131(4):451–457. https://doi.org/10.1016/j.anai.2023.05.036..
DOI: 10.1016/j.anai.2023.05.036
Krings JG, Sekhar TC, Chen V, Blake KV, Sumino K, James AS et al. Beginning to address an implementation gap in asthma: clinicians’ views of prescribing reliever budesonide-formoterol inhalers and SMART in the United States. J Allergy Clin Immunol Pract. 20023;11(9):2767–2777. https://doi.org/10.1016/j.jaip.2023.05.023..
DOI: 10.1016/j.jaip.2023.05.023
Janson C, Melén E, de Fine Licht S, Telg G, Maslova E, Tran TN et al. Prescribing patterns of budesonide/formoterol maintenance and reliever therapy in patients with asthma in Sweden. Allergy. 2023;78(8):2311–2314. https://doi.org/10.1111/all.15710..
DOI: 10.1111/all.15710
Günaydın FE, Ay P, Karakaya G, Ediger D. How do we manage asthma? Assessment of knowledge, attitude, and practice patterns among pulmonologists and allergists. J Asthma. 2023;60(1):130–138. https://doi.org/10.1080/02770903.2022.2033261..
DOI: 10.1080/02770903.2022.2033261
Czira A, Banks V, Requena G, Wood R, Tritton T, Wild R et al. Characterisation of patients with chronic obstructive pulmonary disease initiating single-device inhaled corticosteroids/long-acting β2 -agonist dual therapy in a primary care setting in England. BMJ Open Respir Res. 2022;9(1):e001243. https://doi.org/10.1136/bmjresp-2022-001243..
DOI: 10.1136/bmjresp-2022-001243
Brattsand R, Selroos O. May a different kinetic mode explain the high efficacy/safety profile of inhaled budesonide? Pulm Pharmacol Ther. 2022;77:102167. https://doi.org/10.1016/j.pupt.2022.102167..
DOI: 10.1016/j.pupt.2022.102167
Varacca G, D’Angelo D, Glieca S, Cavalieri L, Piraino A, Quarta E et al. The impact of possible improper use on the performance in vitro of NEXThaler in comparison with Ellipta inhaler. Eur J Pharm Sci. 2023;183:106385. https://doi.org/10.1016/j.ejps.2023.106385..
DOI: 10.1016/j.ejps.2023.106385
Renner A, Marth K, Breyer-Kohansal R, Pohl W. Combined analysis of five non-interventional studies of the effectiveness, tolerability, and safety of the extrafine fixed dose beclomethasone/formoterol combination in the treatment of asthma in Austria. Respir Med. 2023;207:107097. https://doi.org/10.1016/j.rmed.2022.107097..
DOI: 10.1016/j.rmed.2022.107097
Титова ОН, Кузубова НА, Лебедева ЕС, Преображенская ТН. Эффект применения экстрамелкодисперсной комбинации беклометазон/формотерол на ранней стадии формирования модели ХОБЛ. РМЖ. 2022;(2):16–20. Режим доступа: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Effekt_primeneniya_ekstramelkodispersnoy_kombinacii_beklometazonformoterol_naranney_stadii_formirovaniya_modeli_HOBL.https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Effekt_primeneniya_ekstramelkodispersnoy_kombinacii_beklometazonformoterol_naranney_stadii_formirovaniya_modeli_HOBL
Титова ОН, Кузубова НА, Лебедева ЕС, Преображенская ТН. Эффект применения экстрамелкодисперсной комбинации беклометазон/формотерол на ранней стадии формирования модели ХОБЛ. РМЖ. 2022;(2):16–20. Режим доступа: https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Effekt_primeneniya_ekstramelkodispersnoy_kombinacii_beklometazonformoterol_naranney_stadii_formirovaniya_modeli_HOBL.https://www.rmj.ru/articles/bolezni_dykhatelnykh_putey/Effekt_primeneniya_ekstramelkodispersnoy_kombinacii_beklometazonformoterol_naranney_stadii_formirovaniya_modeli_HOBL
Метельский СМ, Давидовская ЕИ, Нагорнов ИВ, Ермолкевич РФ, Богуш ЛС, Рузанов ДЮ, Воробьева ОИ. Место ингаляционных кортикостероидных препаратов в комплексной терапии ХОБЛ с позиций GOLD-2022. Рецепт. 2022;25(5):660–673. https://doi.org/10.34883/PI.2022.25.5.009..
DOI: 10.34883/PI.2022.25.5.009
Bakakos P, Chatziapostolou P, Katerelos P, Efstathopoulos P, Korkontzelou A, Katsaounou P. Extrafine beclometasone dipropionate/formoterol nexthaler on device usability, adherence, asthma control and quality of life. A panhellenic prospective, non-interventional observational study in patients with asthma-the NEXT-Step Study. J Pers Med. 2022;12(2):146. https://doi.org/10.3390/jpm12020146..
DOI: 10.3390/jpm12020146
Luo Z, Lucci G, Santoro L, Topole E, Mariotti F. Pharmacokinetic profile of beclometasone dipropionate/formoterol fumarate administered through a novel dry-powder inhaler in Chinese healthy volunteers. Pulm Pharmacol Ther. 2022;73–74:102129. https://doi.org/10.1016/j.pupt.2022.102129..
DOI: 10.1016/j.pupt.2022.102129
Reddel HK, Brusselle G, Lamarca R, Gustafson P, Anderson GP, Jorup C. Safety and effectiveness of as-needed formoterol in asthma patients taking inhaled corticosteroid (ics)-formoterol or ics-salmeterol maintenance therapy. J Allergy Clin Immunol Pract. 2023;11(7):2104-2114.e3. https://doi.org/10.1016/j.jaip.2023.03.046..
DOI: 10.1016/j.jaip.2023.03.046
Muiser S, Imkamp K, Seigers D, Halbersma NJ, Vonk JM, Luijk BHD et al. Budesonide/formoterol maintenance and reliever therapy versus fluticasone/salmeterol fixed-dose treatment in patients with COPD. Thorax. 2023;78(5):451–458. https://doi.org/10.1136/thorax-2022-219620..
DOI: 10.1136/thorax-2022-219620
Price DB, Henley W, Cançado JED, Fabbri LM, Kerstjens HAM, Papi A et al. Interclass difference in pneumonia risk in copd patients initiating fixed dose inhaled treatment containing extrafine particle beclometasone versus fine particle fluticasone. Int J Chron Obstruct Pulmon Dis. 2022;17:355–370. https://doi.org/10.2147/COPD.S342357..
DOI: 10.2147/COPD.S342357
Jiang T, Li P, Wang Y. Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma-COPD overlap syndrome. Allergol Immunopathol (Madr). 2023;51(4):131–138. https://doi.org/10.15586/aei.v51i4.876..
DOI: 10.15586/aei.v51i4.876
Samajdar SS, Mukherjee S, Moitra S, Pal J, Joshi S, Tripathi SK. Effectiveness of budesonide formoterol fixed-dose combination MDI in reducing cough symptoms in COVID-19 patients: A real-world evidence study. Lung India. 2023;40(2):107–111. https://doi.org/10.4103/lungindia.lungindia_268_22..
DOI: 10.4103/lungindia.lungindia_268_22
van der Veer T, de Koning Gans JM, Braunstahl GJ, Pieters ALP, van den Berg JMW, Hoek RAS et al. The effect of beclomethasone-formoterol versus placebo on chronic cough in patients with non-CF bronchiectasis: the FORZA randomised controlled trial. Eur Respir J. 2023;61(6):2300186. https://doi.org/10.1183/13993003.00186-2023..
DOI: 10.1183/13993003.00186-2023
Maneechotesuwan K, Singh D, Fritscher LG, Dursunoglu NPGA, Phansalkar A, Aggarwal B et al. Impact of inhaled fluticasone propionate/salmeterol on health-related quality of life in asthma: A network meta-analysis. Respir Med. 2022;203:106993. https://doi.org/10.1016/j.rmed.2022.106993..
DOI: 10.1016/j.rmed.2022.106993
Hale EM, Greene G, Mulvey C, Mokoka MC, van Boven JFM, Cushen B et al.; INCA Research Team. Use of digital measurement of medication adherence and lung function to guide the management of uncontrolled asthma (INCA Sun): a multicentre, single-blinded, randomised clinical trial. Lancet Respir Med. 2023;11(7):591–601. https://doi.org/10.1016/S2213-2600(22)00534-3..
DOI: 10.1016/S2213-2600(22)00534-3
Doniec Z, Olszanecka-Glinianowicz M, Hantulik P, Almgren-Rachtan A, Chudek J. The assessment of effectiveness, tolerance, and patient satisfaction with the use of a new fixed-dose combination product, containing salmeterol and fluticasone propionate, Salflumix Easyhaler® in the treatment of asthma in the daily clinical practice. J Asthma. 2023;60(4):754–760. https://doi.org/10.1080/02770903.2022.2093220..
DOI: 10.1080/02770903.2022.2093220
Feldman WB, Kesselheim AS, Avorn J, Russo M, Wang SV. Comparative effectiveness and safety of generic versus brand-name fluticasonesalmeterol to treat chronic obstructive pulmonary disease. Ann Intern Med. 2023;176(8):1047–1056. https://doi.org/10.7326/M23-0615..
DOI: 10.7326/M23-0615
Alyami MH, Dahmash EZ, Ali DK, Alyami HS, AbdulKarim H, Alsudir SA. Novel fluticasone propionate and salmeterol fixed-dose combination nano-encapsulated particles using polyamide based on L-Lysine. Pharmaceuticals (Basel). 2022;15(3):321. https://doi.org/10.3390/ph15030321..
DOI: 10.3390/ph15030321
Mills H, Acquah R, Tang N, Cheung L, Klenk S, Glassen R et al. Biochemical behaviours of salmeterol/fluticasone propionate in treating asthma and chronic obstructive pulmonary diseases (COPD). Emerg Med Int. 2022;2022:2593740. https://doi.org/10.1155/2022/2593740..
DOI: 10.1155/2022/2593740